Jake Y. Henry

New South Wales Department of Health — Australia

Medicine · Health Sciences

23h-index8.2kcitations70works5.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(20), Immunotherapy and Immune Responses(18), Multiple Myeloma Research and Treatments(18), Lung Cancer Treatments and Mutations(11), CAR-T cell therapy research(10)

Publications70 total

Framework-mediated binding of foreign and self-glycans by IGHV4–34 antibodies
Frontiers in Immunology·2026Open Access
Humoral epitope dominance and immune imprinting by <scp>SARS</scp> ‐ <scp>CoV</scp> ‐1 and <scp>SARS</scp> ‐ <scp>CoV</scp> ‐2 vaccines
Immunology and Cell Biology·2026Open Access
Energy-guided combinatorial co-optimization of antibody affinity and stability
2025Open Access
Targeting the NPY/NPY1R signaling axis in mutant p53–dependent pancreatic cancer impairs metastasis
Science Advances·2025· 5 citedOpen Access
Affinity maturation endows potent activity onto class 6 SARS-CoV-2 broadly neutralizing antibodies
Proceedings of the National Academy of Sciences·2025· 5 citedOpen Access
1010P Phase I dose-escalation study of HBM1020: A novel anti-B7H7 antibody in patients with advanced solid tumors
Annals of Oncology·2024
Human genomic DNA is widely interspersed with i-motif structures
The EMBO Journal·2024· 29 citedOpen Access
Supplementary Data from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
2023Open Access
Table S1 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
2023Open Access
Table S1 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
2023Open Access
Table S5 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
2023Open Access
Supplementary Data from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
2023Open Access
Table S4 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
2023Open Access
Table S2 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
2023Open Access
Table S3 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
2023Open Access
Table S2 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
2023Open Access
Data from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
2023Open Access
Data from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
2023Open Access
Table S5 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
2023Open Access
Table S3 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Sergio A. Quezada(25), Andrew J.S. Furness(16), Rachel Rosenthal(13), Charles Swanton(13), Nicholas McGranahan(12), Karl S. Peggs(12), Daniel Christ(11), Teresa Marafioti(10), Ehsan Ghorani(10), Tom Lund(9), Javier Herrero(9), Anthony D. Kelleher(9), Ayse U. Akarca(8), Mary Falzon(8), Angus Dalgleish(8), Gregory J. Walker(8), Peter Schofield(8), Jennifer Jackson(8), Ohan Mazigi(8), William D. Rawlinson(8)